FibroBiologics

About FibroBiologics

FibroBiologics is a company focused on developing fibroblast cell-based therapies to treat and potentially cure chronic diseases. They harness the power of fibroblasts, the most common cell in the human body, as a practical and economical alternative to stem cells for tissue and organ regeneration.

Products & Services

Fibroblast Cell-Based Therapies:Therapies using fibroblasts for tissue regeneration and immune modulation, targeting chronic conditions and organ decline.

CNS Disorders (Multiple Sclerosis):Therapies showing promising pre-clinical and clinical trial data for treating autoimmune diseases like Multiple Sclerosis.

Thymus Therapy:Exploring fibroblast therapies to improve and extend the productive life of the thymus as it declines with age.

Degenerative Disc Disease (DDD):Using fibroblasts as a potential substitute for Mesenchymal stem cells in treating DDD.

Skin (Wound Healing):Leveraging fibroblasts' natural role in the wound healing process for therapeutic applications.

Specialties

Fibroblast Cell-Based Therapies Tissue and Organ Regeneration Immune Modulation Chronic Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1700000 MR: - FA: approximately $1.7 million FAN: 1700000	D: 2025-12-16 FD: 2025-12-16	1 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1700000 MR: - FA: $1.7 million FAN: 1700000	D: 2025-12-15 FD: 2025-12-15	-
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1500000 MR: - FA: $1.5 million FAN: 1500000	D: 2025-11-25 FD: 2025-11-25	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1500000 MR: - FA: approximately $1.5 million FAN: 1500000	D: 2025-11-24 FD: 2025-11-24	-
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4000000 MR: - FA: $4 million FAN: 4000000	D: 2025-11-19 FD: 2025-11-19	1 investors
6	RT: Convertible Debt T: - FT: Convertible Debt	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2025-06-16 FD: 2025-06-16	1 investors
7	RT: Convertible Debt T: - FT: Convertible Debt	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2024-12-30 FD: 2024-12-30	1 investors
8	RT: Convertible Debt T: - FT: Convertible Debt	A: 25000000 MR: - FA: 25 million FAN: 25000000	D: 2024-12-30 FD: 2024-12-30	1 investors
9	RT: Convertible Debt T: - FT: Convertible Debt	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2024-12-23 FD: 2024-12-23	1 investors
10	RT: Equity Crowdfunding T: - FT: Equity Crowdfunding	A: 6900 MR: - FA: surpassing $6,900 per investor FAN: 6900	D: 2023-02-24 FD: 2023-02-24	1 investors
11	RT: Equity Crowdfunding T: - FT: Equity Crowdfunding	A: 1000000 MR: - FA: $1 million FAN: 1000000	D: 2023-02-01 FD: 2023-02-01	2 investors

Registered Direct Offering Latest

2025-12-16

$1.7M

1 investor (Pro only)

Registered Direct Offering 2025-12-15

$1.7M

Registered Direct Offering 2025-11-25

$1.5M

View 10 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Shinya Yamanaka

Nobel Laureate in Physiology or Medicine

P

Pete O'Heeron

Chairman/Founder/CEO

J

Jason D. Davis

Chief Financial Officer

H

Hamid Khoja

Chief Scientific Officer

R

Ruben Garcia

General Counsel

R

Robert E. Hoffman

Director

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

FibroBiologics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised